Cancer-type | Pathway | Q-value | P-value | Pathway size | Cancer set size | DP | DN | GP | GN |
parson_gbm | hsa04510:Focal adhesion | 9.62e-16 | 6.87e-18 | 179 | 254 | 35 | 219 | 179 | 8761 |
parson_gbm | hsa04810:Regulation of actin cytoskeleton | 2.00e-10 | 2.85e-12 | 181 | 254 | 28 | 226 | 181 | 8759 |
parson_gbm | hsa05213:Endometrial cancer | 9.82e-09 | 2.10e-10 | 51 | 254 | 15 | 239 | 51 | 8889 |
parson_gbm | hsa05222:Small cell lung cancer | 3.37e-07 | 1.05e-08 | 83 | 254 | 16 | 238 | 83 | 8857 |
parson_gbm | hsa04670:Leukocyte transendothelial migration | 3.37e-07 | 1.26e-08 | 97 | 254 | 17 | 237 | 97 | 8843 |
parson_gbm | hsa04512:ECM-receptor interaction | 3.37e-07 | 1.45e-08 | 73 | 254 | 15 | 239 | 73 | 8867 |
parson_gbm | hsa05218:Melanoma | 3.75e-07 | 1.88e-08 | 63 | 254 | 14 | 240 | 63 | 8877 |
parson_gbm | hsa05210:Colorectal cancer | 9.34e-07 | 6.5e-08 | 83 | 254 | 15 | 239 | 83 | 8857 |
parson_gbm | hsa05215:Prostate cancer | 9.34e-07 | 6.5e-08 | 83 | 254 | 15 | 239 | 83 | 8857 |
parson_gbm | hsa05214:Glioma | 9.34e-07 | 6.67e-08 | 59 | 254 | 13 | 241 | 59 | 8881 |
parson_gbm | hsa05212:Pancreatic cancer | 1.61e-06 | 1.27e-07 | 75 | 254 | 14 | 240 | 75 | 8865 |
parson_gbm | hsa05223:Non-small cell lung cancer | 2.33e-06 | 2.00e-07 | 54 | 254 | 12 | 242 | 54 | 8886 |
parson_gbm | hsa04020:Calcium signaling pathway | 6.74e-06 | 6.26e-07 | 147 | 254 | 18 | 236 | 147 | 8793 |
parson_gbm | hsa05220:Chronic myeloid leukemia | 4.85e-05 | 4.85e-06 | 76 | 254 | 12 | 242 | 76 | 8864 |
parson_gbm | hsa04070:Phosphatidylinositol signaling system | 7e-05 | 7.64e-06 | 53 | 254 | 10 | 244 | 53 | 8887 |
parson_gbm | hsa04514:Cell adhesion molecules (CAMs) | 7e-05 | 8e-06 | 95 | 254 | 13 | 241 | 95 | 8845 |
parson_gbm | hsa05219:Bladder cancer | 7.39e-05 | 8.97e-06 | 42 | 254 | 9 | 245 | 42 | 8898 |
parson_gbm | hsa01430:Cell Communication | 7.58e-05 | 9.74e-06 | 82 | 254 | 12 | 242 | 82 | 8858 |
parson_gbm | hsa04320:Dorso-ventral axis formation | 7.73e-05 | 1.05e-05 | 22 | 254 | 7 | 247 | 22 | 8918 |
parson_gbm | hsa04910:Insulin signaling pathway | 0.000131 | 1.87e-05 | 120 | 254 | 14 | 240 | 120 | 8820 |
parson_gbm | hsa04150:mTOR signaling pathway | 0.000132 | 1.98e-05 | 47 | 254 | 9 | 245 | 47 | 8893 |
parson_gbm | hsa04080:Neuroactive ligand-receptor interaction | 0.000171 | 2.68e-05 | 197 | 254 | 18 | 236 | 197 | 8743 |
parson_gbm | hsa04010:MAPK signaling pathway | 0.000238 | 3.92e-05 | 223 | 254 | 19 | 235 | 223 | 8717 |
parson_gbm | hsa02010:ABC transporters - General | 0.000278 | 4.77e-05 | 19 | 254 | 6 | 248 | 19 | 8921 |
parson_gbm | hsa04930:Type II diabetes mellitus | 0.000326 | 5.97e-05 | 42 | 254 | 8 | 246 | 42 | 8898 |
parson_gbm | hsa00020:Citrate cycle (TCA cycle) | 0.000326 | 6.06e-05 | 20 | 254 | 6 | 248 | 20 | 8920 |
parson_gbm | hsa04012:ErbB signaling pathway | 0.000330 | 6.37e-05 | 85 | 254 | 11 | 243 | 85 | 8855 |
parson_gbm | hsa04530:Tight junction | 0.000367 | 7.53e-05 | 103 | 254 | 12 | 242 | 103 | 8837 |
parson_gbm | hsa05221:Acute myeloid leukemia | 0.000367 | 7.6e-05 | 57 | 254 | 9 | 245 | 57 | 8883 |
parson_gbm | hsa04662:B cell receptor signaling pathway | 0.000506 | 0.000108 | 60 | 254 | 9 | 245 | 60 | 8880 |
parson_gbm | hsa04360:Axon guidance | 0.000557 | 0.000123 | 109 | 254 | 12 | 242 | 109 | 8831 |
parson_gbm | hsa04370:VEGF signaling pathway | 0.000594 | 0.000136 | 62 | 254 | 9 | 245 | 62 | 8878 |
parson_gbm | hsa04610:Complement and coagulation cascades | 0.000856 | 0.000208 | 66 | 254 | 9 | 245 | 66 | 8874 |
parson_gbm | hsa05211:Renal cell carcinoma | 0.000856 | 0.000208 | 66 | 254 | 9 | 245 | 66 | 8874 |
parson_gbm | hsa04330:Notch signaling pathway | 0.00111 | 0.000276 | 40 | 254 | 7 | 247 | 40 | 8900 |
parson_gbm | hsa04520:Adherens junction | 0.00131 | 0.000340 | 71 | 254 | 9 | 245 | 71 | 8869 |
parson_gbm | hsa00650:Butanoate metabolism | 0.00131 | 0.000346 | 18 | 254 | 5 | 249 | 18 | 8922 |
parson_gbm | hsa00252:Alanine and aspartate metabolism | 0.00153 | 0.000427 | 19 | 254 | 5 | 249 | 19 | 8921 |
parson_gbm | hsa00561:Glycerolipid metabolism | 0.00153 | 0.000427 | 19 | 254 | 5 | 249 | 19 | 8921 |
parson_gbm | hsa00620:Pyruvate metabolism | 0.00217 | 0.000632 | 21 | 254 | 5 | 249 | 21 | 8919 |
parson_gbm | hsa04540:Gap junction | 0.00217 | 0.000637 | 78 | 254 | 9 | 245 | 78 | 8862 |
parson_gbm | hsa04664:Fc epsilon RI signaling pathway | 0.00316 | 0.000948 | 66 | 254 | 8 | 246 | 66 | 8874 |
parson_gbm | hsa00562:Inositol phosphate metabolism | 0.00353 | 0.00108 | 37 | 254 | 6 | 248 | 37 | 8903 |
parson_gbm | hsa04730:Long-term depression | 0.0036 | 0.00113 | 68 | 254 | 8 | 246 | 68 | 8872 |
parson_gbm | hsa04660:T cell receptor signaling pathway | 0.00404 | 0.00130 | 87 | 254 | 9 | 245 | 87 | 8853 |
parson_gbm | hsa04630:Jak-STAT signaling pathway | 0.00406 | 0.00133 | 125 | 254 | 11 | 243 | 125 | 8815 |
parson_gbm | hsa05217:Basal cell carcinoma | 0.00568 | 0.00194 | 42 | 254 | 6 | 248 | 42 | 8898 |
parson_gbm | hsa05216:Thyroid cancer | 0.00568 | 0.00195 | 28 | 254 | 5 | 249 | 28 | 8912 |
parson_gbm | hsa04115:p53 signaling pathway | 0.00627 | 0.00219 | 59 | 254 | 7 | 247 | 59 | 8881 |
parson_gbm | hsa04720:Long-term potentiation | 0.0073 | 0.00261 | 61 | 254 | 7 | 247 | 61 | 8879 |
parson_gbm | hsa04210:Apoptosis | 0.00742 | 0.0027 | 79 | 254 | 8 | 246 | 79 | 8861 |
parson_gbm | hsa05030:Amyotrophic lateral sclerosis (ALS) | 0.00883 | 0.00333 | 19 | 254 | 4 | 250 | 19 | 8921 |
parson_gbm | hsa04310:Wnt signaling pathway | 0.00883 | 0.00334 | 121 | 254 | 10 | 244 | 121 | 8819 |
parson_gbm | hsa04650:Natural killer cell mediated cytotoxicity | 0.0116 | 0.00448 | 106 | 254 | 9 | 245 | 106 | 8834 |
parson_gbm | hsa03030:DNA polymerase | 0.0116 | 0.00455 | 21 | 254 | 4 | 250 | 21 | 8919 |
parson_gbm | hsa04620:Toll-like receptor signaling pathway | 0.0124 | 0.00496 | 88 | 254 | 8 | 246 | 88 | 8852 |
parson_gbm | hsa00010:Glycolysis / Gluconeogenesis | 0.0155 | 0.00632 | 38 | 254 | 5 | 249 | 38 | 8902 |
parson_gbm | hsa03022:Basal transcription factors | 0.0189 | 0.00785 | 25 | 254 | 4 | 250 | 25 | 8915 |
parson_gbm | hsa00280:Valine, leucine and isoleucine degradation | 0.0248 | 0.0106 | 14 | 254 | 3 | 251 | 14 | 8926 |
parson_gbm | hsa01032:Glycan structures - degradation | 0.0248 | 0.0106 | 14 | 254 | 3 | 251 | 14 | 8926 |
parson_gbm | hsa05010:Alzheimer's disease | 0.0256 | 0.0111 | 28 | 254 | 4 | 250 | 28 | 8912 |
parson_gbm | hsa00640:Propanoate metabolism | 0.0282 | 0.0125 | 15 | 254 | 3 | 251 | 15 | 8925 |
parson_gbm | hsa04110:Cell cycle | 0.0286 | 0.0129 | 105 | 254 | 8 | 246 | 105 | 8835 |
parson_gbm | hsa00230:Purine metabolism | 0.0312 | 0.0143 | 86 | 254 | 7 | 247 | 86 | 8854 |
parson_gbm | hsa04614:Renin-angiotensin system | 0.0313 | 0.0146 | 16 | 254 | 3 | 251 | 16 | 8924 |
parson_gbm | hsa00564:Glycerophospholipid metabolism | 0.039 | 0.0184 | 33 | 254 | 4 | 250 | 33 | 8907 |
parson_gbm | hsa00600:Sphingolipid metabolism | 0.0395 | 0.0192 | 18 | 254 | 3 | 251 | 18 | 8922 |
parson_gbm | hsa05020:Parkinson's disease | 0.0395 | 0.0192 | 18 | 254 | 3 | 251 | 18 | 8922 |
parson_gbm | hsa00500:Starch and sucrose metabolism | 0.0484 | 0.0239 | 36 | 254 | 4 | 250 | 36 | 8904 |
parson_gbm | hsa00251:Glutamate metabolism | 0.0491 | 0.0245 | 20 | 254 | 3 | 251 | 20 | 8920 |
parson_gbm | hsa01510:Neurodegenerative Diseases | 0.0552 | 0.028 | 38 | 254 | 4 | 250 | 38 | 8902 |
parson_gbm | hsa00511:N-Glycan degradation | 0.0575 | 0.0296 | 8 | 254 | 2 | 252 | 8 | 8932 |
parson_gbm | hsa04742:Taste transduction | 0.0587 | 0.0306 | 22 | 254 | 3 | 251 | 22 | 8918 |
parson_gbm | hsa04120:Ubiquitin mediated proteolysis | 0.0668 | 0.0353 | 105 | 254 | 7 | 247 | 105 | 8835 |
parson_gbm | hsa04060:Cytokine-cytokine receptor interaction | 0.0734 | 0.0393 | 207 | 254 | 11 | 243 | 207 | 8733 |
parson_gbm | hsa00590:Arachidonic acid metabolism | 0.0827 | 0.0449 | 26 | 254 | 3 | 251 | 26 | 8914 |
parson_gbm | hsa00410:beta-Alanine metabolism | 0.0871 | 0.0485 | 11 | 254 | 2 | 252 | 11 | 8929 |
parson_gbm | hsa00903:Limonene and pinene degradation | 0.0871 | 0.0485 | 11 | 254 | 2 | 252 | 11 | 8929 |
parson_gbm | hsa00910:Nitrogen metabolism | 0.112 | 0.063 | 13 | 254 | 2 | 252 | 13 | 8927 |
parson_gbm | hsa00240:Pyrimidine metabolism | 0.114 | 0.0649 | 51 | 254 | 4 | 250 | 51 | 8889 |
parson_gbm | hsa04640:Hematopoietic cell lineage | 0.116 | 0.067 | 74 | 254 | 5 | 249 | 74 | 8866 |
parson_gbm | hsa00220:Urea cycle and metabolism of amino groups | 0.121 | 0.0707 | 14 | 254 | 2 | 252 | 14 | 8926 |
parson_gbm | hsa00710:Carbon fixation | 0.133 | 0.0788 | 15 | 254 | 2 | 252 | 15 | 8925 |
parson_gbm | hsa03320:PPAR signaling pathway | 0.142 | 0.0867 | 35 | 254 | 3 | 251 | 35 | 8905 |
parson_gbm | hsa00565:Ether lipid metabolism | 0.142 | 0.087 | 16 | 254 | 2 | 252 | 16 | 8924 |
parson_gbm | hsa04140:Regulation of autophagy | 0.142 | 0.087 | 16 | 254 | 2 | 252 | 16 | 8924 |
parson_gbm | hsa04912:GnRH signaling pathway | 0.143 | 0.0891 | 81 | 254 | 5 | 249 | 81 | 8859 |
parson_gbm | hsa00071:Fatty acid metabolism | 0.166 | 0.104 | 18 | 254 | 2 | 252 | 18 | 8922 |
parson_gbm | hsa04740:Olfactory transduction | 0.178 | 0.113 | 19 | 254 | 2 | 252 | 19 | 8921 |
parson_gbm | hsa00260:Glycine, serine and threonine metabolism | 0.190 | 0.122 | 20 | 254 | 2 | 252 | 20 | 8920 |
parson_gbm | hsa04340:Hedgehog signaling pathway | 0.205 | 0.133 | 43 | 254 | 3 | 251 | 43 | 8897 |
parson_gbm | hsa00330:Arginine and proline metabolism | 0.230 | 0.151 | 23 | 254 | 2 | 252 | 23 | 8917 |
parson_gbm | hsa00790:Folate biosynthesis | 0.242 | 0.161 | 24 | 254 | 2 | 252 | 24 | 8916 |
parson_gbm | hsa00310:Lysine degradation | 0.254 | 0.170 | 25 | 254 | 2 | 252 | 25 | 8915 |
parson_gbm | hsa05040:Huntington's disease | 0.281 | 0.190 | 27 | 254 | 2 | 252 | 27 | 8913 |
parson_gbm | hsa00380:Tryptophan metabolism | 0.322 | 0.221 | 30 | 254 | 2 | 252 | 30 | 8910 |
parson_gbm | hsa04920:Adipocytokine signaling pathway | 0.375 | 0.260 | 61 | 254 | 3 | 251 | 61 | 8879 |
parson_gbm | hsa00120:Bile acid biosynthesis | 0.379 | 0.265 | 10 | 254 | 1 | 253 | 10 | 8930 |
parson_gbm | hsa00360:Phenylalanine metabolism | 0.392 | 0.286 | 11 | 254 | 1 | 253 | 11 | 8929 |
parson_gbm | hsa00361:gamma-Hexachlorocyclohexane degradation | 0.392 | 0.286 | 11 | 254 | 1 | 253 | 11 | 8929 |
parson_gbm | hsa00591:Linoleic acid metabolism | 0.392 | 0.286 | 11 | 254 | 1 | 253 | 11 | 8929 |
parson_gbm | hsa00740:Riboflavin metabolism | 0.392 | 0.286 | 11 | 254 | 1 | 253 | 11 | 8929 |
parson_gbm | hsa01030:Glycan structures - biosynthesis 1 | 0.398 | 0.293 | 37 | 254 | 2 | 252 | 37 | 8903 |
parson_gbm | hsa05060:Prion disease | 0.411 | 0.305 | 12 | 254 | 1 | 253 | 12 | 8928 |
parson_gbm | hsa00512:O-Glycan biosynthesis | 0.433 | 0.325 | 13 | 254 | 1 | 253 | 13 | 8927 |
parson_gbm | hsa00150:Androgen and estrogen metabolism | 0.449 | 0.343 | 14 | 254 | 1 | 253 | 14 | 8926 |
parson_gbm | hsa03020:RNA polymerase | 0.449 | 0.343 | 14 | 254 | 1 | 253 | 14 | 8926 |
parson_gbm | hsa00980:Metabolism of xenobiotics by cytochrome P450 | 0.469 | 0.361 | 15 | 254 | 1 | 253 | 15 | 8925 |
parson_gbm | hsa00340:Histidine metabolism | 0.483 | 0.379 | 16 | 254 | 1 | 253 | 16 | 8924 |
parson_gbm | hsa00480:Glutathione metabolism | 0.483 | 0.379 | 16 | 254 | 1 | 253 | 16 | 8924 |
parson_gbm | hsa04916:Melanogenesis | 0.49 | 0.389 | 78 | 254 | 3 | 251 | 78 | 8862 |
parson_gbm | hsa00052:Galactose metabolism | 0.491 | 0.396 | 17 | 254 | 1 | 253 | 17 | 8923 |
parson_gbm | hsa00510:N-Glycan biosynthesis | 0.491 | 0.396 | 17 | 254 | 1 | 253 | 17 | 8923 |
parson_gbm | hsa04350:TGF-beta signaling pathway | 0.503 | 0.411 | 81 | 254 | 3 | 251 | 81 | 8859 |
parson_gbm | hsa01031:Glycan structures - biosynthesis 2 | 0.503 | 0.413 | 18 | 254 | 1 | 253 | 18 | 8922 |
parson_gbm | hsa05120:Epithelial cell signaling in Helicobacter pylori infection | 0.545 | 0.452 | 53 | 254 | 2 | 252 | 53 | 8887 |
parson_gbm | hsa03050:Proteasome | 0.551 | 0.460 | 21 | 254 | 1 | 253 | 21 | 8919 |
parson_gbm | hsa00350:Tyrosine metabolism | 0.581 | 0.49 | 23 | 254 | 1 | 253 | 23 | 8917 |
parson_gbm | hsa04130:SNARE interactions in vesicular transport | 0.64 | 0.544 | 27 | 254 | 1 | 253 | 27 | 8913 |
parson_gbm | hsa04940:Type I diabetes mellitus | 0.664 | 0.569 | 29 | 254 | 1 | 253 | 29 | 8911 |
parson_gbm | hsa05130:Pathogenic Escherichia coli infection - EHEC | 0.785 | 0.684 | 40 | 254 | 1 | 253 | 40 | 8900 |
parson_gbm | hsa05131:Pathogenic Escherichia coli infection - EPEC | 0.785 | 0.684 | 40 | 254 | 1 | 253 | 40 | 8900 |
parson_gbm | hsa03010:Ribosome | 0.788 | 0.693 | 41 | 254 | 1 | 253 | 41 | 8899 |
parson_gbm | hsa00030:Pentose phosphate pathway | 1 | 1 | 18 | 254 | 0 | 254 | 18 | 8922 |
parson_gbm | hsa00051:Fructose and mannose metabolism | 1 | 1 | 22 | 254 | 0 | 254 | 22 | 8918 |
parson_gbm | hsa00100:Biosynthesis of steroids | 1 | 1 | 11 | 254 | 0 | 254 | 11 | 8929 |
parson_gbm | hsa00190:Oxidative phosphorylation | 1 | 1 | 49 | 254 | 0 | 254 | 49 | 8891 |
parson_gbm | hsa00440:Aminophosphonate metabolism | 1 | 1 | 10 | 254 | 0 | 254 | 10 | 8930 |
parson_gbm | hsa00450:Selenoamino acid metabolism | 1 | 1 | 13 | 254 | 0 | 254 | 13 | 8927 |
parson_gbm | hsa00530:Aminosugars metabolism | 1 | 1 | 13 | 254 | 0 | 254 | 13 | 8927 |
parson_gbm | hsa00626:Naphthalene and anthracene degradation | 1 | 1 | 10 | 254 | 0 | 254 | 10 | 8930 |
parson_gbm | hsa00632:Benzoate degradation via CoA ligation | 1 | 1 | 9 | 254 | 0 | 254 | 9 | 8931 |
parson_gbm | hsa00860:Porphyrin and chlorophyll metabolism | 1 | 1 | 13 | 254 | 0 | 254 | 13 | 8927 |
parson_gbm | hsa00930:Caprolactam degradation | 1 | 1 | 10 | 254 | 0 | 254 | 10 | 8930 |
parson_gbm | hsa00970:Aminoacyl-tRNA biosynthesis | 1 | 1 | 16 | 254 | 0 | 254 | 16 | 8924 |
parson_gbm | hsa04612:Antigen processing and presentation | 1 | 1 | 54 | 254 | 0 | 254 | 54 | 8886 |
parson_gbm | hsa04710:Circadian rhythm | 1 | 1 | 12 | 254 | 0 | 254 | 12 | 8928 |
parson_gbm | hsa04950:Maturity onset diabetes of the young | 1 | 1 | 18 | 254 | 0 | 254 | 18 | 8922 |
parson_gbm | hsa05050:Dentatorubropallidoluysian atrophy (DRPLA) | 1 | 1 | 13 | 254 | 0 | 254 | 13 | 8927 |
parson_gbm | hsa05110:Cholera - Infection | 1 | 1 | 28 | 254 | 0 | 254 | 28 | 8912 |